ECSP19017505A - CELLULAR METABOLIC PROCESS INHIBITORS - Google Patents

CELLULAR METABOLIC PROCESS INHIBITORS

Info

Publication number
ECSP19017505A
ECSP19017505A ECSENADI201917505A ECDI201917505A ECSP19017505A EC SP19017505 A ECSP19017505 A EC SP19017505A EC SENADI201917505 A ECSENADI201917505 A EC SENADI201917505A EC DI201917505 A ECDI201917505 A EC DI201917505A EC SP19017505 A ECSP19017505 A EC SP19017505A
Authority
EC
Ecuador
Prior art keywords
metabolic process
cellular metabolic
process inhibitors
inhibitors
chemical
Prior art date
Application number
ECSENADI201917505A
Other languages
Spanish (es)
Inventor
Ye Zhixiong
D Konteatis Zenon
M Travins Jeremy
Sui Zhihua
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Priority to ECSENADI201917505A priority Critical patent/ECSP19017505A/en
Publication of ECSP19017505A publication Critical patent/ECSP19017505A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Lo adjunto detalla: - Resumen - Reinvindicaciones - Campos de Invención - Antecedentes - Descripción Detallada - Tablas de Composición Química - Esquemas de las Composiciones Química - Métodos de Uso - Composiciones Farmaceuticas - Ejemplos - Notas Experimentales Generales.The attached details: - Abstract - Claims - Fields of Invention - Background - Detailed Description - Chemical Composition Tables - Schemes of Chemical Compositions - Methods of Use - Pharmaceutical Compositions - Examples - General Experimental Notes.

ECSENADI201917505A 2019-03-13 2019-03-13 CELLULAR METABOLIC PROCESS INHIBITORS ECSP19017505A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSENADI201917505A ECSP19017505A (en) 2019-03-13 2019-03-13 CELLULAR METABOLIC PROCESS INHIBITORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSENADI201917505A ECSP19017505A (en) 2019-03-13 2019-03-13 CELLULAR METABOLIC PROCESS INHIBITORS

Publications (1)

Publication Number Publication Date
ECSP19017505A true ECSP19017505A (en) 2019-05-31

Family

ID=69897303

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201917505A ECSP19017505A (en) 2019-03-13 2019-03-13 CELLULAR METABOLIC PROCESS INHIBITORS

Country Status (1)

Country Link
EC (1) ECSP19017505A (en)

Similar Documents

Publication Publication Date Title
EA201890749A1 (en) ACETHYL-COA-CARBOXYLASE INHIBITORS (ACC) AND THEIR APPLICATION
CR20200393A (en) Picolinamides as fungicides
PH12020500655A1 (en) Compounds
EA201992235A1 (en) SYNTHESIS INHIBITOR MCL-1
EA201792205A1 (en) HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
EA201890926A1 (en) TRIAZOLE ACETHYL-COA-CARBOXYLASE INHIBITORS AND THEIR OPTIONS
ECSP21001499A (en) ANTIBODIES TARGETED AGAINST IL-11RA
MX2018001430A (en) New bicyclic compounds as dual atx/ca inhibitors.
MA51616A (en) DNA-PK INHIBITORS
UY37834A (en) MH TREATMENT WITH PIRIMIDINADIONA COMPOUNDS
MX2018001890A (en) Bicyclic compounds as atx inhibitors.
MX2018002217A (en) Bicyclic compounds as atx inhibitors.
BR112017026682A2 (en) new bicyclic compounds as dual action inhibitors of atx / ca
EA201591959A1 (en) ACC INHIBITORS AND THEIR APPLICATION
EA201591960A1 (en) ACC INHIBITORS AND THEIR APPLICATION
EA201792021A1 (en) JAK INHIBITOR
EA201591962A1 (en) ACC INHIBITORS AND THEIR APPLICATION
CY1124338T1 (en) 3-PHOSPHOGLYCERATE DEHYDROGENATION INHIBITORS AND THEIR USES
EA202190475A1 (en) MINI-GDE FOR TREATMENT OF GLYCOGENOSIS TYPE III
CL2019001804A1 (en) Nrf2 activator.
EA201892051A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MALIGNANT NON-FORMATION
EA201792288A1 (en) METHODS OF TREATING CANCER
CL2022001452A1 (en) Masp-2 inhibitors and methods of use.
ECSP19017505A (en) CELLULAR METABOLIC PROCESS INHIBITORS
CL2020002881A1 (en) Use of canakinumab